Skip to content

The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment

The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery (MBCR) During Chemotherapy Treatment (CT) to Impact Fatigue, Side Effects and Quality of Life (QL) in a Randomized Waitlist Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03484000
Enrollment
178
Registered
2018-03-30
Start date
2018-06-01
Completion date
2025-01-01
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Chemotherapy Effect, Colorectal Cancer

Brief summary

Background: Chemotherapy treatment (CT) can have burdensome side effects such as fatigue, nausea-vomiting, and sleep problems that can significantly affect patients' quality of life. Fatigue is the most common, lasting and bothersome of these, which prevents people from working and carrying out daily activities. Mindfulness-Based Cancer Recovery (MBCR) is an evidence-based group training program which has shown to help treat negative physical and psychosocial symptoms in cancer patients. The investigators propose to evaluate a pilot-tested online-MBCR program for patients undergoing CT who may be low on energy, time or have compromised immunity. Objectives: To evaluate the impact of participation in online MBCR during CT on fatigue (primary outcome), sleep, pain, nausea/vomiting, mood disturbance, stress symptoms and quality of life (secondary outcomes) as well as cognitive function and return to work (exploratory outcomes) over the course of treatment. Methods: The study design is a randomized wait-list controlled trial, conducted during CT for patients with breast or colorectal cancer. Participants will take the 12-week online MBCR program at home within 2 weeks of randomization (immediate group) or after CT completion (waitlist group). Outcomes will be assessed online at, 1) Baseline, 2) Post-MBCR, 3) Post-CT (primary outcome) and 4) 12 months post-baseline. Anticipated Findings: MBCR is a promising adjuvant program that could help patients prevent, delay or diminish aversive symptoms and side-effects associated with CT, particularly fatigue. If helpful, online-MBCR could be made easily available at cancer centers worldwide and significantly lessen the burden of cancer treatments.

Interventions

BEHAVIORALOnline Mindfulness Based Cancer Recovery (MBCR)

MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Men and women over the age of 18 2. Diagnosed with either a) stage I-III HER 2 normal breast carcinoma or b) Stage II-III colorectal carcinoma 3. Scheduled to undergo either neoadjuvant or adjuvant: a) FEC- D or AC-T chemotherapy or b) FOLFOX or CAPEOX chemotherapy 4. Weekly access to high-speed internet 5. Access to a computer/tablet/smart phone 6. Able to attend MBCR classes at scheduled times 7. Sufficient ability to speak and read English 8. Willingness to be randomized into immediate or waitlist groups and complete all assessments

Exclusion criteria

1. Metastatic patients 2. Suffering from current Major Depressive Disorder, Bipolar Disorder or other psychiatric disorder (self-report) 3. Currently engaging in meditation one or more times per week within the previous year. 4. Participation in an MBCR or MBSR program in the last five years. 5. Cognitive impairment (\>6 on the Brief Screen for Cognitive Impairment) 6. Physical functional impairment that would interfere with the ability to participate in the intervention (on the PAR-Q questionnaire)

Design outcomes

Primary

MeasureTime frameDescription
Fatigue6 monthsFatigue will be measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F 68) is the most commonly-used cancer-related fatigue scale. Using a 5-point Likert scale (from not at all to very much), the 13-items reflect participants' specific fatigue concerns in the past 7 days. The total score has well-established norms both in the literature and from our prior work and shows responsiveness to intervention

Countries

Canada

Contacts

Primary ContactLinda E Carlson, PhD
lcarlso@ucalgary.ca14033553207

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026